《大行報告》中銀國際上調康方生物(09926.HK)目標價至65元 評級「買入」
中銀國際發表評級報告指,康方生物(09926.HK)去年收入按年升440%至45億元人民幣,受惠技術授權和技術合作收入(licence income)29億元人民幣及藥品AK104強勁銷售增長149%至13.6億元人民幣。該行指,淨虧損收窄至7.88億元人民幣,受惠研發及銷售開支精簡。
該行指,考慮到2024年大部份時間沒有新適應症獲得批准,以及行業持續整頓的影響揮之不去,並有機會影響短期銷售,該行將AK104收入預測下調至16億元人民幣,但維持長遠看好AK104。鑑於集團高營運效率、快速的管道進展以及未來的多重催化劑,該行將其目標價由59元上調至65元,維持評級「買入」。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.